# **Patisiran: Temperature Excursions**

The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.

The full Prescribing Information for ONPATTRO<sup>®</sup> (patisiran) is provided <u>here</u>. Alnylam Pharmaceuticals does not recommend the use of its products in any manner that is inconsistent with the approved Prescribing Information. This resource may contain information that is not in the approved Prescribing Information.

If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at <u>RNAiScience.com</u>.

## **INDEX**

<u>Impact of Temperature Excursions</u> – <u>Label Information</u> – <u>Abbreviations</u> – <u>References</u>

## IMPACT OF TEMPERATURE EXCURSIONS

#### **Impact of Temperature Excursions**

Patisiran is shipped and stored at the storage condition of 2 to  $8^{\circ}$ C and carries a "do not freeze" recommendation on the label. During shipment or storage, patisiran may potentially be exposed to a temperature below the lower limit of the defined recommended storage condition of  $2^{\circ}$ C, or above the upper limit of the defined recommended storage condition of  $8^{\circ}$ C.<sup>1</sup>

In one analysis, the stability of patisiran following exposure at low temperatures was evaluated using stability-indicating chemical analyses that measured change as a function of time for quantitative attributes (siRNA and lipid excipient content) and adherence to key quality attributes including physical appearance, pH, particle size, drug substance purity, and percent encapsulation of the siRNA. The study concluded that, after exposing patisiran to a low temperature of -4°C for up to 96 hours, patisiran did not freeze and is chemically and physically stable.<sup>1,2</sup>

In another analysis, the stability of patisiran following exposure at high temperatures was evaluated using stability-indicating chemical analyses that measured change as a function of time for quantitative attributes (siRNA and lipid excipient content) and adherence to key quality attributes including physical appearance, pH, osmolality, particle size, drug substance purity, and percent encapsulation of the siRNA. The study concluded that, due the susceptibility of the drug product to thermal degradation, storage above 30°C should be limited. The existing stability data conservatively supports short-term temperature excursions of up to 40°C, and these excursions should not exceed 24 hours in duration.<sup>1,3</sup>

Overall, there is no product quality impact to patisiran when subjected to temperature excursions of not lower than  $-4^{\circ}$ C for up to 96 hours or for up to 40°C for up to 24 hours (**Table 1**).<sup>1–3</sup>

Table 1. Temperature Excursion and Duration with No Product Q	uality Impact to Patisiran. <sup>1–3</sup>
· · · · · · · · · · · · · · · · · · ·	

Temperature Excursion	Duration
Not lower than -4°C	Up to 96 hours
Up to 40°C	Up to 24 hours

The assessment is based on the abovementioned excursion followed by storage at 2°C to 8°C as per the USPI.

#### **ONPATTRO PRESCRIBING INFORMATION – RELEVANT CONTENT**

The HOW SUPPLIED/STORAGE AND HANDLING section provides the following information<sup>4</sup>: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard vial if it has been frozen.

If refrigeration is not available, ONPATTRO can be stored at room temperature up to  $25^{\circ}C$  (up to  $77^{\circ}F$ ) for up to 14 days.

#### **ABBREVIATIONS**

siRNA = small interfering ribonucleic acid; USPI = US Prescribing Information.

Updated 17 October 2023

#### REFERENCES

- 1. Alnylam Pharmaceuticals. Data on file. MED-ALL-TTR02-2200017.
- 2. Alnylam Pharmaceuticals. Data on file. MED-ALL-TTR02-2100027.
- 3. Alnylam Pharmaceuticals. Data on file. MED-ALL-TTR02-1900226.
- 4. ONPATTRO (patisiran) Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.